Business Context and Reporting Period
This Form 8-K is filed by Renovaro Inc. (not Lunai Bioworks Inc.) on July 14, 2025. The report addresses a regulatory compliance issue regarding the company's listing on The Nasdaq Stock Market LLC under the symbol RENB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Non-Compliance Notice: On July 7, 2025, Renovaro Inc. received a notice from Nasdaq stating it failed to comply with Listing Rule 5620(a).
- Reason for Non-Compliance: The company did not hold its annual meeting of shareholders within twelve months of its fiscal year end on June 30, 2024.
- Current Status: The notice does not immediately affect the listing or trading of the company's common stock.
Guidance, Outlook, and Risks
- Compliance Plan: The company has 45 calendar days from the notice date to submit a plan to regain compliance.
- Extension Possibility: If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the fiscal year end (until December 29, 2025) to hold the meeting.
- Delisting Risk: If the company fails to submit a timely plan or if Nasdaq rejects the plan, the common stock may be subject to delisting.
- Management Intent: Management intends to submit a compliance plan and hold the annual meeting as soon as practicable.
Investor Verification Checklist
- Verify the exact date the company submits its compliance plan to Nasdaq (deadline is within 45 days of July 7, 2025).
- Confirm whether Nasdaq accepts the submitted plan and grants the potential 180-day extension.
- Monitor for the scheduling of the annual meeting of shareholders to ensure it occurs before the December 29, 2025 deadline.
- Review subsequent filings for any updates on the delisting risk status.